Novo Nordisk CEO Rules Out Large M&A Deals Amid Pipeline Setbacks
Novo Nordisk prioritizes bolt-on acquisitions over transformative deals as pipeline challenges persist in obesity and diabetes markets. Novo Nordisk CEO Maziar Mike Doustdar stated the company is not positioned for large-scale M&A, despite pipeline setbacks including faile